Editorial overview: Immunomodulation: Striking the right balance: using immunomodulators to target infectious diseases, cancer, and autoimmunity
Section snippets
Ed Lavelle graduated with a BSc in Microbiology from University College Galway and a PhD in Immunology from the University of Plymouth. He carried our postdoctoral research at the University of Nottingham on nano and microparticles as vaccine adjuvants. This was followed by further postdoctoral positions at the Rowett Research Institute and Trinity College Dublin (TCD) on vaccine adjuvants and immunomodulators. He was appointed as a lecturer in 2004, associate Professor in 2012 and Professor in
References (10)
- et al.
Immune evasion in cancer: mechanistic basis and therapeutic strategies
Semin Cancer Biol
(2015) - et al.
The impact of past vaccination coverage and immunity on pertussis resurgence
Sci Transl Med
(2018) - et al.
Acellular pertussis vaccines protect against disease but fail to prevent infection and transmission in a nonhuman primate model
Proc Natl Acad Sci USA
(2014) - et al.
From empiricism to rational design: a personal perspective of the evolution of vaccine development
Nat Rev Immunol
(2014) - et al.
The evolution of seasonal influenza viruses
Nat Rev Microbiol
(2018)
Cited by (7)
The pro-invasive factor COL6A2 serves as a novel prognostic marker of glioma
2022, Frontiers in OncologyExpression and clinical significance of CXCL17 and GPR35 in endometrial carcinoma
2022, Anti-Cancer DrugsProfiles of immune infiltration in the tumor microenvironment of hepatocellular carcinoma
2021, Journal of Gastrointestinal OncologyAdjuvants: friends in vaccine formulations against infectious diseases
2021, Human Vaccines and Immunotherapeutics
Ed Lavelle graduated with a BSc in Microbiology from University College Galway and a PhD in Immunology from the University of Plymouth. He carried our postdoctoral research at the University of Nottingham on nano and microparticles as vaccine adjuvants. This was followed by further postdoctoral positions at the Rowett Research Institute and Trinity College Dublin (TCD) on vaccine adjuvants and immunomodulators. He was appointed as a lecturer in 2004, associate Professor in 2012 and Professor in Immunology at TCD in 2015. He is currently Head of the School of Biochemistry and Immunology at TCD and President of the Irish Society for Immunology. His main research area is the mechanism by which particulate adjuvants modulate innate and adaptive immune responses with a strong focus on translating this work to develop novel adjuvants for injectable and mucosal vaccines.
James McLachlan obtained his B.A. in Biology from Appalachian State University and then received a PhD from Duke University where he studied the role of mast cells in the initiation of the adaptive immune response. He went on to perform postdoctoral research at the University of Minnesota – Twin Cities, exploring the intricacies of helper T cell responses in non-lymphoid tissues. He joined the faculty of the Tulane University School of Medicine in the Department of Microbiology and Immunology in 2009 as an Assistant Professor and was promoted to Associate Professor in 2015. His group is interested in the immunological mechanisms of vaccine efficacy and vaccine design as well as understanding cellular immune responses to intracellular bacterial infections.